Lobbying Information
Subject Matters
- Aboriginal Affairs
- Constitutional Issues
- Economic Development
- Education
- Government Procurement
- Health
- Industry
- Intellectual Property
- International Development
- International Relations
- International Trade
- Privacy and Access to Information
- Regional Development
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Policies or Program
- Canada's Access to Medicines Regime (CAMR) with regard to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
- Canada's Food and Consumer Safety Action Plan with regard to ensuring that patient safety is a priority in a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
- Cost Recovery Initiative, ensuring a framework where user fees adequately fund a safe and efficient review process.
- National Pharmaceutical Strategy (NPS) with regard to ensuring development or implementation of any policies or programs include consultations with all affected stakeholders and focus on bettering access to medicines for Canadians.
- Patented Medicines Price Review Board (PMPRB) with regard to ensuring that PMPRB Guidelines, Policies and Procedures reflect PMPRB mandate to ensure that prices charged for patented medicines in Canada are not excessive and that potential changes consider impact to the pharmaceutical industry.
- Public policy issues related to Health Canada's review of NCE
- Science and Technology (S&T) Strategy with regard to ensuring that the implementation of that strategy encourages a public policy environment that attracts business investment in innovation and enhances the ability of Canadian industry to compete internationally.
- Scientific Research and Experimental Development (SR&ED) Tax Incentive Program with regard to expansion of eligible expenditures to recognize the impact on innovation and the research and development (R&D) investment by the pharmaceutical industry in Canada.
- The Canada-European Union Comprehensive Economic and Trade Agreement (CETA) negotiations with respect to biopharmaceuticals and intellectual property right protection.
- Through Innovation, Science & Industry discuss opportunities to enhance the Canadian life sciences sector including, biomanufacturing, partnerships, R&D investments.
Policies or Program, Regulation
- Blueprint for Renewal with regard to ensuring a modern, efficient and internationally harmonized regulatory system that must be evidence-based, efficient and continuous while supporting timely access to innovative medicines and vaccines for Canadians, protecting intellectual property rights and preserving competitive research advantage.
- Representation with Ministry of Health and Public Service Procurement Canada to achieve emergency approval, procurement and utilization of the AZD1222 vaccine (Covishield) and long-acting antibody (LAAB) combination AZD7442 to fight the Covid-19 pandemic.
Regulation
- Patented Medicine Prices Review Board (PMPRB) with regard to ensuring guidelines also provide incentives for innovation through research and development in addition to PMPRB mandate of protection from excessive prices.
- Patented Medicines (Notice Of Compliance) Regulations with regard to ensuring that Canada's intellectual property (IP) laws and regulations are internationally competitive and continue to provide a stable and predictable business environment to encourage continued pharmaceutical investment in Canada.
Communication Techniques
-
Written communication
-
Oral communication
Government Institutions
-
Agriculture and Agri-Food Canada (AAFC)
-
Atlantic Canada Opportunities Agency (ACOA)
-
Canada Economic Development for Quebec Regions
-
Canada Foundation for Innovation
-
Canada Revenue Agency (CRA)
-
Canadian Institutes of Health Research (CIHR)
-
Canadian International Trade Tribunal (CITT)
-
Canadian Northern Economic Development Agency (CanNor)
-
Competition Bureau Canada (COBU)
-
Federal Economic Development Agency for Southern Ontario (FedDev)
-
Finance Canada (FIN)
-
Global Affairs Canada (GAC)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
International Development Research Centre (IDRC)
-
National Defence (DND)
-
National Research Council (NRC)
-
Natural Sciences and Engineering Research Council (NSERC)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Public Health Agency of Canada (PHAC)
-
Public Services and Procurement Canada (PSPC)
-
Royal Canadian Mounted Police (RCMP)
-
Senate of Canada
-
Treasury Board Of Canada Secretariat (TBS)
-
Veterans Affairs Canada (VAC)
In-house Corporation Details
Description of activities
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca’s Canadian headquarters are located in Mississauga, Ontario. For more information, please visit the company’s website at www.astrazeneca.ca.
Responsible officer name and position during the period of this registration
Gaby Bourbara,
President
Government funding
No government funding was received during the last completed financial year.
In-house Corporation Contact Information
Address:
1004 Middlegate Road, Suite 5000
Mississauga, ON L4Y 1M4
Canada
Telephone number:
800-565-5877
Parent Company Information
- AstraZeneca PLC
-
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB20AA
United Kingdom
Subsidiary Beneficiary Information
AstraZeneca Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyists Details
Senior Officers whose lobbying activities represent less than 20% of their Duties
- Denise Lacombe,
Head of Legal |
No public offices held
- Pascal Soriot,
Chief Executive |
No public offices held
Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties
- Jon Feairs,
Director, Government Affairs & Public Policy |
No public offices held
- Isabelle Gagnon,
Senior Manager, Government Affairs Federal |
No public offices held
- Ilias Iliopoulos,
Interim Market Access & Pricing Lead |
No public offices held
- Carlo Mastrangelo,
Head - Corporate Affairs, Communications & Sustainability |
No public offices held
- Heather McDonald,
Vice President, Market Access and Pricing |
No public offices held
- Dale Payne,
Senior Manager, National Policy and Partnerships |
No public offices held
- Gena Restivo,
VP, Corporate Affairs & Sustainability |
No public offices held
- Alex Romanovschi,
Vice President, Scientific Affairs |
No public offices held
- Jean-Sebastien Roy,
Director, Strategic Pricing |
No public offices held
- Noel Saraza,
Senior Manager, Payer Relations |
No public offices held
- Kathleen Whelan,
Director, Government Affairs, Alexion Pharma Canada |
No public offices held
